Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.65 USD | +2.48% | +4.34% | +157.80% |
Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Apr. 10 | Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.16B |
---|---|---|---|---|---|
Net income 2024 * | -118M | Net income 2025 * | -130M | EV / Sales 2024 * | - |
Net Debt 2024 * | 293M | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-18.3
x | P/E ratio 2025 * |
-16.9
x | Employees | 51 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.05% |
Latest transcript on Vera Therapeutics, Inc.
1 day | +2.48% | ||
1 week | +4.34% | ||
Current month | -8.05% | ||
1 month | -4.64% | ||
3 months | +31.38% | ||
6 months | +287.59% | ||
Current year | +157.80% |
Managers | Title | Age | Since |
---|---|---|---|
Marshall Fordyce
FOU | Founder | 50 | 16-04-30 |
Sean Grant
DFI | Director of Finance/CFO | 39 | 21-07-11 |
Kerry Cooper
CTO | Chief Tech/Sci/R&D Officer | - | 23-05-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 16-05-31 |
Chairman | 63 | 22-05-23 | |
Patrick Enright
BRD | Director/Board Member | 62 | 20-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 39.65 | +2.48% | 856,779 |
24-04-25 | 38.69 | -3.15% | 850,183 |
24-04-24 | 39.95 | +1.09% | 773,165 |
24-04-23 | 39.52 | +1.00% | 1,216,328 |
24-04-22 | 39.13 | +2.97% | 714,101 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+157.80% | 2.16B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VERA Stock